)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Zura Bio
Zura Bio (ZURA) investor relations material
Zura Bio Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary27 Oct, 2026
Company overview and business model
Clinical-stage biotech developing antibody medicines for serious autoimmune and inflammatory diseases with unmet medical need; focus on immune pathways supported by translational and clinical evidence.
Lead candidate tibulizumab (ZB-106), in Phase 2 trials, is designed to block IL-17 and B-cell activating factor; pipeline also includes clinical-stage antibody assets.
Financial performance and metrics
Net tangible book value at September 30, 2026 was $177.7 million, or $1.84/share; under the assumed ATM sale, adjusted value would be $287.8 million, or $2.24/share.
As of September 30, 2026, 96,306,411 Class A shares were outstanding; outstanding options, restricted share units, pre-funded warrants and plan reserves create potential additional dilution.
Significant losses have been incurred since inception; significant losses are expected for the foreseeable future, with substantial additional capital required to fund operations.
Use of proceeds and capital allocation
ATM net proceeds are intended for working capital and general corporate purposes, including R&D, manufacturing, commercialization and strategic transactions; management retains broad discretion over use.
Pending deployment, proceeds may be invested; the base prospectus specifies short-term, investment-grade interest-bearing obligations, CDs or U.S. government obligations.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Zura Bio
- Three Phase 2 catalysts anchor a dual-pathway immune pipeline through 2027.ZURA
Corporate presentation - $187.7M cash supports advancing tibulizumab trials, with HS results expected in Q4 2026.ZURAQ3 2026
- Phase II data for a dual-pathway antibody in HS may redefine treatment standards.ZURA12th Annual Cantor Fitzgerald Global Healthcare Conference
- Advancing a first-in-class bispecific antibody for major immune diseases, with strong funding and pipeline.ZURACorporate presentation
- Q2 net loss rose to $26.3M as R&D spending surged; cash runway extends through 2028.ZURAQ2 2026
- Lead assets in SSc and HS target 2026 readouts, with major external catalysts expected in 2025.ZURAPiper Sandler 36th Annual Healthcare Conference
- Tibulizumab targets dual immune pathways in HS and SSc, with pivotal Phase 2 data expected by 2027.ZURACorporate presentation
- Tibulizumab targets dual immune pathways in Phase 2 trials for HS and SSc, aiming for market leadership.ZURACorporate presentation
- Director resignation and proxy materials filed; Class A shares continue trading on Nasdaq.ZURAProxy filing
Next Zura Bio earnings date
Q4 202619 Mar, 2027
Zura Bio
Next Zura Bio earnings date
Q4 202619 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Zura Bio Limited is a clinical-stage biotechnology company focused on developing innovative therapies for immune and inflammatory disorders. It leverages multi-asset immunology to create novel dual-pathway antibodies, including tibulizumab, ZB-168, and torudokimab, which are designed to address autoimmune diseases and other conditions with unmet medical needs. These therapies have completed early-phase studies and are advancing towards further clinical development. Zura Bio Limited is headquartered in Henderson, Nevada, and its shares are listed on NASDAQ.